Merck KGaA (FRA:MRK) received a €95.00 ($117.28) target price from stock analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Monday. The brokerage currently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.’s price objective would suggest a potential upside of 15.43% from the stock’s previous close.
A number of other brokerages have also recently weighed in on MRK. Oddo Bhf set a €125.00 ($154.32) price target on Merck KGaA and gave the stock a “buy” rating in a research report on Friday, November 10th. Nord/LB reaffirmed a “neutral” rating on shares of Merck KGaA in a research report on Tuesday, January 2nd. DZ Bank reaffirmed a “neutral” rating on shares of Merck KGaA in a research report on Tuesday, November 14th. UBS Group reaffirmed a “buy” rating on shares of Merck KGaA in a research report on Monday, January 15th. Finally, Kepler Capital Markets set a €115.00 ($141.98) price target on Merck KGaA and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Twelve analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Merck KGaA has a consensus rating of “Hold” and an average target price of €107.57 ($132.80).
Shares of Merck KGaA (FRA MRK) opened at €82.30 ($101.60) on Monday. Merck KGaA has a 12-month low of €80.50 ($99.38) and a 12-month high of €115.00 ($141.98). The firm has a market capitalization of $10,430.00 and a PE ratio of 19.27.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2018/02/12/merck-kgaa-mrk-given-a-95-00-price-target-at-jpmorgan-chase-co.html.
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.